GIP在2型糖尿病与肥胖中的临床潜力
本文综述了肠促胰素药理学在2型糖尿病和肥胖治疗中的进展,重点讨论替尔泊肽作为GLP-1R/GIPR双激动剂的有效性,并探讨GIPR激动与拮抗机制在未来药物开发中的潜在应用。
要点
- 替尔泊肽是当前最有效的GLP-1R/GIPR双激动剂。
- GIPR与GLP-1R对替尔泊肽临床效应的相对贡献尚未明确。
- GIPR激动和拮抗策略均可能用于2型糖尿病与肥胖治疗。
核心结论
- 替尔泊肽的疗效重新激发了GIPR激动在代谢药理中的临床兴趣。
研究设计与样本
- 本文为综述,讨论肠促胰素生物学及其与代谢药理学的关联。
主要发现
- 替尔泊肽是迄今最有效的药物,为同时作用于GLP-1R和GIPR的双激动剂。
- GIPR和GLP-1R作用对替尔泊肽临床效应的相对贡献尚未确定。
临床怎么用
- GIPR激动剂和拮抗剂可能为2型糖尿病和肥胖治疗提供新选择。
局限性
- GIPR与GLP-1R对替尔泊肽临床效应的相对贡献尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Incretin-based pharmacology has revolutionized the medical treatment of type 2 diabetes and obesity. The most effective drug to date is tirzepatide, a dual incretin receptor agonist that engages both the glucagon-like peptide 1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). While the relative contributions of GIPR and GLP-1R actions to the clinical effects of tirzepatide have not been established, the potency of this agent has reignited interest in the clinical potential of GIPR agonism. Here, we discuss incretin biology as it relates to metabolic pharmacology and contextualize the mechanisms by which GIPR activity could contribute to the development of new and effective drugs. We explore current and future applications of GIPR agonists and antagonists, to underscore the potential that this signaling system could add to treatment of type 2 diabetes and obesity.
引用
- Nauck M, Gribble F, Reimann F, et al. Clinical Potential of GIP in Type 2 Diabetes and Obesity. Diabetes Care. 2026. PMID: 41973737. doi:10.2337/dci25-0141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。